|Application ||WB, IF, E|
|Other Accession||NP_008984, 5901910|
|Calculated MW||Predicted: 20 kDa |
|Application Notes||CD160 antibody can be used for detection of CD160 by Western blot at 1 - 2 µg/ml.|
|Target/Specificity||CD160; CD160 antibody is human and mouse reactive. Multiple isoforms of CD160 are known to exist.|
|Reconstitution & Storage||CD160 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year.|
|Precautions||CD160 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Receptor showing broad specificity for both classical and non-classical MHC class I molecules.|
|Cellular Location||Cell membrane; Lipid-anchor, GPI-anchor.|
|Tissue Location||Expressed in spleen, peripheral blood, and small intestine. Expression is restricted to functional NK and T cytotoxic lymphocytes|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CD160, also known as BY55, is a lipid-anchored cell membrane glycoprotein that contains one immunoglobulin-like domain (1). It is expressed in small intestine, spleen and functional NK and T cytotoxic lymphocytes (1,2). CD160 exists as a disulfide-linked homomultimer that functions as a receptor for MHC (major histocompatability complex) molecules and is thought to regulate the function of NK cells (2,3). Additionally, CD160 interacts with TNFRSF14 and, via this interaction, is able to negatively regulate CD4+ T cell activation, indicating a role in immune system regulation (4).
Anumanthan A, Bensussan A, Boumsell L, et al. Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. J. Immunol. 1998; 161:2780-90.
Agrawal S, Marquet J, Freeman GJ, et al. Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells. J. Immunol. 1999; 162:1223-6.
Le Bouteiller P, Tabiasco J, Polgar B, et al. CD160: a unique activating NK cell receptor. Immunol. Lett. 2011;138:93-6
Chabot S, Jabrane-Ferrat N, Bigot K, et al. A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor. J. Exp. Med. 2011; 208:973-86.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.